Member Info for Brighty1

"we are entering a pivotal time for the Company over the next six months and I look forward to providing further updates as each work stream progresses" - Nigel Theobald CEO, RNS Nov 2020

"The recent success of Pfizer and Moderna with an mRNA Covid-19 vaccine shows the potential for nucleic acid vaccines. However, it also highlights that these vaccines have certain limitations, in that they often require extreme storage conditions" - Nigel Theobald CEO, RNS Dec 2020

"We believe, to the extent that Nuvec® as a delivery platform can provide a solution in this area, it could be of significant interest to multiple vaccine developers". Nigel Theobald CEO, RNS Dec 2020

Here's to the next few months. We are due an update soon. Good luck, Brighty

Hopefully this is the start of exciting gains for BWNG investors. At the start of 2020 we were at 150p+ per share, just 11 months ago. Lots of multiple gains to be made here as I have no doubt that we will be above 100p per share in early 2021 and heading towards 200p per share with a resumption of the dividend. As I've said before BWNG is the "Right share at the right time". Dyor, here's to next year and good luck, Brighty

In addition to the great strides made by Tek Capital's Salarius business with its low sodium salt product is taking off in the USA, one of the other key businesses in the TEK Capital portfolio is Guident, which as we know develops technology to enhance the utility, safety and enjoyment of autonomous vehicles. Apple's plans to to launch its electric car production by 2024 could therefore be good news for Guident. Apple''s electric car will be available for the mass market and would compete with other manufacturers such as Tesla. Good luck, Brighty

George Stapleton, Petroteq COO, commented: "While we had hoped to restart the POSP last week, we should now be able to operate more or less continuously following the restart, without any planned Holiday shutdowns ahead of us. The test results obtained for the sand tailings are a welcome outcome. Any revenue received from the sale of frac sand and/or aggregate is expected to assist us in lowering the operating costs for the POSP, thereby providing higher than expected netbacks per barrel of oil produced." It's starting to look interesting now for TOM. Roll on Jan 4th. Good luck, Brighty

Yes, quite right. Just will be back to over 100p per share and back to its 150p range soon. Dyor but a reminder that from the interims they stated they were expecting: 'significantly higher' sales in the second half of the year after reporting that first-half profit more than doubled. For the six months ended 30 June 2020, pre-tax profit rose to £305m from £125m. Good luck, Brighty

Quite a few £10,000 and £12,000 approx buys being reported now in the 2.2p to 2.4p range from earlier today. Bodes well. Good luck, Brighty

Yes, 2.44p just paid Aber. 30% rises per day are welcome also! Good luck, Brighty

Steady 10% per day rises are fine by me! Good luck, Brighty

The 2 significant commercial messages in the Spud RNS today are:
"a potential uplift that is the traditional domain of the 'oil majors'.
"targeting oil resources of 0.77 billion barrels, with an upside of 1.44 billion barrels"
Good luck, Brighty

Just to add that we've also had some historic research success with Merck MSD in the last 18 months. i.e. Back in June 2019 via SRA737. You will recall that SRA737's data showing the 100% regression of tumors after 21 days in small cell lung cancer (ICB -Keytruda MSD). So Sareum will certainly be on Merck MSD's radar regarding how effective Tim and John's science is and how it could be used in their cytokine storm research. Plus don't forget that Merck MSD is the 5th biggest pharma in the world and has very deep pockets for licencing and M&A. One to watch in the coming weeks and months. Good luck, Brighty
1.Johnson & Johnson – $56.1bn.
2. Pfizer – $51.75bn.
3. Roche – $49.23bn.
4. Novartis – $47.45bn.
5. Merck & Co. – $46.84bn.

On June 25th Merck MSD announced that the FDA had given IND for M5049, which is its phase 2 study on reducing the inflammatory response that leads to ‘cytokine storm’. They said at the time Phase 2 results would be expected by the end of 2020. I would say that would make MSD a possible suitor for either licencing or M&A with Sareum. Good luck, Brighty

3 RNS announcements condensed in to 1 cracking RNS. Fantastic day for all Synairgen investors.

- SNG001 given Fast Track designation and IND cleared by the US FDA

- Phase III trial design adapted which will expedite results

- Phase III trial to commence dosing in UK imminently

Good luck, Brighty

The best bit for me is: Paul Baay CEO of Touchstone commented: "This agreement provides a stable, multi-decade revenue stream for Touchstone to fully develop the world-class asset at Ortoire. This transforms the company from being an exploration company to one that is a full cycle energy provider. The structure of the agreement provides the shareholders of Touchstone with a predictable cash flow and earnings stream for years to come while minimising the capital required to maximise the resource." End of year 150p looks to be on....Here's to 250p per share in 2021. Good luck, Brighty

Based on July of this year we had a period of sustained daily rises from 15th July with the share price at 6p to 21st July with the share price at over 17p intra day. Back in 2017 we had 5 days of huge gains when PYC announced a relatively small contract win (with a major pharma) in November 2017 the share price went from 1.3p to 4.2p in one day. It then climbed the next day from 5p to 10p. It then climbed the following day from 10p as high as 32p before closing at 17.1p. Anything is possible with PYC. See below. Good luck, Brighty

PYC chart covering Nov 28th 2017 to Dec 1st 2017 below
Date Open High Low Close Vol
Nov 30, 2017 10.51 32.00 9.50 17.125 49,900,790
Nov 29, 2017 5.00 10.00 3.77 9.50 78,119,582
Nov 28, 2017 1.30 4.2659 1.235 4.25 102,217,619

Interesting development re TRHC DoseMRx and the statement in the RNS just now about "The next step being a commercial agreement". Good luck, Brighty

Nice one. Your Lupus post back in July was also very informative pre the RNS, Citizen. Keep them coming. Very helpful. Good luck, Brighty

Yes, exciting times as we await the very significant Evotec update and don't forget that on November 5th the RNS stated that an update before the year end was likely: "Feasibility work continues on Nuvec® as a solution to the challenges faced in the delivery of vaccines orally. The Company expects to have some data following the results of planned studies as to its viability towards the end of this year". Plus Nigel Theobald did say that "we are entering a pivotal time for the Company over the next six months and I look forward to providing further updates as each work stream progresses."
In the same RNS it was also stated; "Development of an orally administered vaccine has significantly greater challenges than a subcutaneous injection. One important aspect is that the DNA plasmid may be subject to damage and breakdown by gastric acid and other digestive processes. However, the Company has now demonstrated that Nuvec® protects plasmid DNA from both acid and nuclease digestion. This result gives the Company confidence that further investigation of this route of administration using Nuvec® is merited". All in all looking very very interesting and don't forget about those "collaborations" that Nigel has mentioned. Good luck, Brighty

Num4, I agree that we must be getting very very close to human trials of our Tyk2, as Tim indicated on 25th June 2019 in an RNS that this was the aim "as quickly as possible, aiming for first-in-man studies to begin in 2020". Good luck, Brighty

More online success. Whilst not in our sector the online messaging is relevant here re Dixons: Electricals and mobile phone retailer Dixons Carphone reported a swing to interim profit as online sales surged.

Revenue for the half-year to October 31 rose to GBP4.86 billion from GBP4.71 billion a year ago, with Dixons turning to a pretax profit of GBP45 million from a GBP86 million loss.

"We're winning online, and have triple-digit growth and rapid market share gains to show for it," said Chief Executive Alex Baldock.

Good luck, Brighty

I agree with you that future news (and I would add £££ revenue) is not priced in. Novacyt has shown that once potential revenue is factored in by the market the share price reacts accordingly. With what our CEO has had to say our revenue is going to leap exponentially and once the market takes this on board our share price will re-rate accordingly. It's just a matter of time. A good RNS or two confirming contracts will do the trick. Good luck, Brighty